Pay in 4 interest-free payments of $7.40 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Without insurance, tirzepatide can cost approximately $1,000 monthly, and coverage changes or prior authorization denials may force patients to stop treatment abruptly
The STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial programme demonstrated that adults using semaglutide 2.4 mg weekly alongside lifestyle intervention lost an average of approximately 15% of their body weight over 68 weeks, compared to around 2.4% with placebo. NICE approved Wegovy for use in specialist weight management services in the UK in 2023 (TA875), recognising its clinical effectiveness. Ongoing research continues to explore its cardiovascular benefits, with the SELECT trial showing a significant reduction in major cardiovascular events in people with obesity
Some BCBS planslike BCBS South Carolinacover Zepbound for OSA with a sleep study showing 15 events/hour and BMI 30
CNS-targeting pharmacological interventions for the metabolic syndrome
These effects lower blood glucose and reduce appetite, supporting weight loss
US$ 28.67
US$ 25.23
US$ 25.78
